Therefore, blocking the CD36-dependent pathway is expected to be a therapeutic strategy for a variety of kidney diseases, and novel CD36-targeting peptides have the ability of slowing the progression of CKD [107]. The gene discussed is CD36; the disease is chronic kidney disease.